Drugs that contain Aminolevulinic Acid Hydrochloride
1. Ameluz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559183 | BIOFRONTERA | Nano-emulsion of 5-aminolevulinic acid |
Nov, 2019
(4 years ago) | |
| US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(3 years from now) | |
| US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 10, 2019 |
Market Authorisation Date: 10 May, 2016
Treatment: Treatment of actinic keratoses by photodynamic therapy; Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illu...
Dosage: GEL;TOPICAL
AMELUZ family patents
2. Levulan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5079262 | DUSA | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
Sep, 2013
(10 years ago) | |
| US5954703 | DUSA | Method and apparatus for applying 5-aminolevulinic acid |
Oct, 2017
(6 years ago) | |
| US6709446 | DUSA | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
May, 2018
(5 years ago) | |
| US8758418 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
| US8216289 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
| US7723910 | DUSA | Method of photodynamically diagnosing or treating a contoured surface |
Jun, 2019
(4 years ago) | |
| US11135293 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11571478 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11690914 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11077192 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-766) | Mar 09, 2021 |
| M(M-82) | Mar 12, 2013 |
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL
LEVULAN family patents